Literature DB >> 24681727

MAP4K4 deletion inhibits proliferation and activation of CD4(+) T cell and promotes T regulatory cell generation in vitro.

Hongpeng Huang1, Qiuqiong Tang1, Hongqian Chu1, Jianjun Jiang1, Haizhou Zhang2, Weidong Hao3, Xuetao Wei4.   

Abstract

CD4(+) T cells are critical for adaptive immunity. MAP4K4 is a key member of germinal center kinase group. However, the physiological function of MAP4K4 in primary CD4(+) T cells is still unclear. In this study, it was demonstrated that in vitro, MAP4K4 deletion remarkably suppressed CD4(+) T cell proliferation in response to phorbol 12-myristate 13-acetate (PMA) and ionomycin, which was not due to enhancing cell apoptosis. Additionally, MAP4K4 was required for the activation of CD4(+) T cells. MAP4K4 deletion significantly down-regulated expression of interleukin 2 (IL-2) and interferon-γ (IFN-γ), while notably up-regulating the expression of regulatory T cells (Treg) transcription factor Foxp3 in peripheral CD4(+) T cells. Furthermore, western blot analysis indicated that CD4(+) T cells lacking MAP4K4 failed to phosphorylate Jnk, Erk, p38 and PKC-θ. Thus, our results provide the evidence that MAP4K4 is essential for CD4(+) T cell proliferation, activation and cytokine production.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; MAP4K4; PKC-θ; Treg

Mesh:

Substances:

Year:  2014        PMID: 24681727     DOI: 10.1016/j.cellimm.2014.02.006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

Review 1.  Map4k4 Signaling Nodes in Metabolic and Cardiovascular Diseases.

Authors:  Joseph V Virbasius; Michael P Czech
Journal:  Trends Endocrinol Metab       Date:  2016-05-06       Impact factor: 12.015

2.  STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.

Authors:  Jong Wook Kim; Christian Berrios; Miju Kim; Amy E Schade; Guillaume Adelmant; Huwate Yeerna; Emily Damato; Amanda Balboni Iniguez; Laurence Florens; Michael P Washburn; Kim Stegmaier; Nathanael S Gray; Pablo Tamayo; Ole Gjoerup; Jarrod A Marto; James DeCaprio; William C Hahn
Journal:  Elife       Date:  2020-01-08       Impact factor: 8.140

3.  BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice.

Authors:  Gaelle Auguste; Leila Rouhi; Scot J Matkovich; Cristian Coarfa; Matthew J Robertson; Grazyna Czernuszewicz; Priyatansh Gurha; Ali J Marian
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 4.  MAP4K4: an emerging therapeutic target in cancer.

Authors:  Xuan Gao; Chenxi Gao; Guoxiang Liu; Jing Hu
Journal:  Cell Biosci       Date:  2016-10-28       Impact factor: 7.133

5.  Hsa-let-7c-5p augments enterovirus 71 replication through viral subversion of cell signaling in rhabdomyosarcoma cells.

Authors:  Bingfei Zhou; Min Chu; Shanshan Xu; Xiong Chen; Yongjuan Liu; Zhihao Wang; Fengfeng Zhang; Song Han; Jun Yin; Biwen Peng; Xiaohua He; Wanhong Liu
Journal:  Cell Biosci       Date:  2017-01-14       Impact factor: 7.133

6.  m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response.

Authors:  Ruiqing Yu; Qimeng Li; Zhihui Feng; Luhui Cai; Qiong Xu
Journal:  Int J Mol Sci       Date:  2019-03-15       Impact factor: 5.923

7.  Vascular smooth muscle RhoA counteracts abdominal aortic aneurysm formation by modulating MAP4K4 activity.

Authors:  Md Rasel Molla; Akio Shimizu; Masahiro Komeno; Nor Idayu A Rahman; Joanne Ern Chi Soh; Le Kim Chi Nguyen; Mahbubur Rahman Khan; Wondwossen Wale Tesega; Si Chen; Xiaoling Pang; Miki Tanaka-Okamoto; Noriyuki Takashima; Akira Sato; Tomoaki Suzuki; Hisakazu Ogita
Journal:  Commun Biol       Date:  2022-10-07

8.  HGK promotes metastatic dissemination in prostate cancer.

Authors:  Sara Garcia-Garcia; Maria Rodrigo-Faus; Noelia Fonseca; Sara Manzano; Balázs Győrffy; Alberto Ocaña; Paloma Bragado; Almudena Porras; Alvaro Gutierrez-Uzquiza
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.